Figure 1From: Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402Vitiligo in patient P2 and P3. Vitiligo appeared throughout the body during the 1st course of vaccination in P2 and P3. Representative finding of vitiligo was observed in the posterior portion of the neck in P2 (A) and the anterior tibial portion of the left leg in patient P3 (B).Back to article page